• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Braun Donald P was granted 5,011 shares, increasing direct ownership by 116% to 9,319 units (SEC Form 4)

    5/27/26 4:12:35 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMNN alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Braun Donald P

    (Last)(First)(Middle)
    C/O IMUNON, INC.
    997 LENOX DRIVE, SUITE 100

    (Street)
    LAWRENCEVILLE NEW JERSEY 08648

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Imunon, Inc. [ IMNN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    05/22/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock05/22/2026A5,011(1)A$2.29,319D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. Stock granted in lieu of cash for portion of board fees
    Remarks:
    On August 21, 2025, the Issuer paid a 15% stock dividend, 0.15 shares of common stock per share of the Issuer's issued and outstanding shares of common stock, to stockholders of record as of August 7, 2025. As a result of the stock dividend, the shares of Issuer Common Stock have been adjusted accordingly versus any amounts previously reported by the Reporting Person.
    /s/ Susan Eylward, Attorney-in-Fact for Donald P. Braun05/27/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $IMNN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMNN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IMNN
    Leadership Updates

    Live Leadership Updates

    View All

    IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer

    Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology and immunology LAWRENCEVILLE, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the appointment of Douglas V. Faller, M.D., Ph.D., as chief medical officer, effective February 18, 2025. In this role, Dr. Faller will lead the company's clinical strategy including advancing its lead program IMNN-001 for the treatment of newly diagnosed advanced ovarian cancer, which is on track to enter a Phase 3 pivotal trial in the first quarter of 202

    2/10/25 8:05:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO

    Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experience in drug development and business strategy LAWRENCEVILLE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced the appointment of Stacy R. Lindborg, Ph.D. as President and Chief Executive Officer, effective May 13, 2024. Dr. Lindborg has served on IMUNON's board of directors since 2021. Dr. Lindborg assumes the leadership of IMUNON at a pivotal time. Topline results from the Phase 2 OVATION 2 Stud

    5/8/24 8:00:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Accomplished pharmaceutical and biotechnology executive to lead IMUNON's clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Sebastien Hazard, M.D. as Chief Medical Officer, effective December 11, 2023. Dr. Hazard brings to IMUNON a strong background in building and leading clinical development organizations, most recently at Bicycle Therapeutics. He will report to IMUNON's President and Chief Executive Officer, Dr. Corinne Le

    12/11/23 8:30:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    SEC Filings

    View All

    SEC Form S-8 filed by Imunon Inc.

    S-8 - Imunon, Inc. (0000749647) (Filer)

    6/17/26 4:15:30 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Imunon Inc.

    8-K - Imunon, Inc. (0000749647) (Filer)

    6/16/26 5:30:17 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Imunon Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Imunon, Inc. (0000749647) (Filer)

    6/4/26 8:00:40 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    Financials

    Live finance-specific insights

    View All

    IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update

    IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by Q1 2029, supported by remarkable Phase 2 data showing significant overall survival improvement FDA has reviewed and is aligned with Phase 3 protocol, confirms path to BLA Filing Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported fin

    5/12/26 8:00:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026

    LAWRENCEVILLE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, May 12, 2026 to discuss financial results for the first quarter ended March 31, 2026 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer. To participate in the call, please dial 800-715-9871 (U.S. and Canada/Toll Free) or 646-307-1963 (U

    5/5/26 8:30:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026

    LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, March 31, 2026 to discuss financial results for the year ended December 31, 2025, and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy. The Company is hosting a conference call to review 2025 financial results and provide a business update on March 31, 2026 at 11:00 a.m. EDT. To participate in the call, please dial 800-715-9871 (North America/Toll Free) or 646-307-1

    3/24/26 8:00:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Braun Donald P bought $29,480 worth of shares (25,000 units at $1.18), increasing direct ownership by 4,188% to 25,597 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    1/28/25 4:18:24 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Lindborg Stacy bought $24,500 worth of Imunon Common Stock (25,000 units at $0.98), increasing direct ownership by 10% to 264,166 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    8/16/24 8:03:50 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chairman of Board Tardugno Michael H bought $25,750 worth of Imunon Common Stock (25,000 units at $1.03), increasing direct ownership by 8% to 353,346 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    8/16/24 8:01:30 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman of Board Tardugno Michael H was granted 4,629 shares, increasing direct ownership by 36% to 17,467 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    6/23/26 7:59:08 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Lindborg Stacy was granted 1,803 shares, increasing direct ownership by 34% to 7,038 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    6/23/26 4:17:54 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chairman of Board Tardugno Michael H was granted 4,089 shares, increasing direct ownership by 47% to 12,838 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    6/9/26 5:15:53 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th

    NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here. "This week's Life Sciences Virtual Investor Forum brings

    6/23/26 8:35:00 AM ET
    $MTVA
    $NSRX
    $CTSO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Industrial Specialties

    IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification

    On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer Novel immunotherapy technology demonstrating unprecedented IL-12 safety profile and extraordinary Phase 2 efficacy LAWRENCEVILLE, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the independent Data Monitoring Committee (iDMC) has recommended continuation of the pivotal Phase 3 OVATION 3 clinical trial evaluating IMNN-001 in combination with standard of care (SoC) neoa

    6/23/26 8:00:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON to Present at the Life Sciences Investor Forum on June 25th

    LAWRENCEVILLE, N.J., June 22, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON, will present at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on Thursday, June 25, 2026, at 12:00 p.m. ET. DATE: Thursday, June 25th, 2026TIME: 12:00 p.m. ETWebcast Registration Link HereAvailable for 1x1 meetings: Schedule 1x1 Meetings HERE This will be a live, interactive online event where investors are invited to ask the Company questions in real-time. If attendees are not able to join the event liv

    6/22/26 4:15:00 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Imunon Inc.

    SC 13G - Imunon, Inc. (0000749647) (Subject)

    11/14/24 5:37:34 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Imunon Inc.

    SC 13G/A - Imunon, Inc. (0000749647) (Subject)

    11/14/24 12:17:50 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Imunon Inc.

    SC 13G - Imunon, Inc. (0000749647) (Subject)

    8/5/24 11:53:32 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care